



## **BIOPHARMACEUTICALS**



## Increased Resolution with HALO 400 Å Diphenyl Compared to FPP 300 Å Diphenyl

Application Note: 207-PR





HALO 400 Å Diphenyl, 3.4 μm Particle Shell with 400 Å pores

Denosumab, a human IgG2 monoclonal antibody that is used to treat cancer in the bones was analyzed on two different types of HPLC columns. The HALO 400 Å column outperformed the 300 Å fully porous diphenyl column by providing much better resolution at 2.5-fold lower back pressure along with a quicker run time.

## **TEST CONDITIONS:**

**Columns**: HALO 400 Å Diphenyl, 3.4 μm, 2.1x150 mm

**Part Number**: 93412-726

FPP 300 Å Diphenyl, 1.8 µm, 2.1x150 mm

Mobile Phase A: 88/10/2: Water/Acetonitrile/\*\*n-Prop/

0.1% \*DFA

Mobile Phase B: 70/20/10: \*\*nProp/Acetonitrile/Water/

0.1% \*DFA

Gradient: Time (min.) %B

0.0 18 20.0 28

Flow Rate: 0.2 mL/min.

HALO® SPP Initial Back Pressure: 89 bar FPP Initial Back Pressure: 240 bar

**Temperature**: 60 °C

**Detection**: 220 nm, PDA **Injection Volume**: 2 μL

Sample Solvent: Water/ 0.1% DFA

Data Rate: 100 Hz

Response Time: 0.025 sec.

Flow Cell: 1 µL

**LC System**: Shimadzu Nexera X2 \*DFA = difluoroacetic acid

\*\*nProp = n- propanol